Entry and fusion inhibitors of HIV

Bibliography

• COCCHI F, DE VICO AL, GARZINO-DEMO A, ARYA RC, GALLO RC, LUSSO P: Identification of RANTES, MIP-la, MIP-1 13 as the major HIV-1-suppressive factors produced by CD8+ cells. Science (1995) 270: 1811-1815.
   Google Scholar
• ••A pivotal paper that described a new potentialapproach against HIV-1 for the first time.
   Google Scholar
• BEN-BARUCH A, MICHIEL DF, OPPENHEIM JJ: Signal and receptors involved in recruitment of inflammatory cells. Biol. Chem. (1995) 270(20):11703–11706.
   Web of Science ®Google Scholar
• CAO Y, QIN L, ZHANG L, SAFRIT J, HO DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus Type 1 infection. N Engl. J. Med. (1995) 332(4):201–208.
   PubMed Web of Science ®Google Scholar
• SHEARER GM, CLERICI M: Cytokine profiles in HIV Type 1 disease and protection. AIDS Res. Hum. Retrovimses (1998) 14\(Supp1.2):S149–S152.
   Google Scholar
• CLERICI M, BALOTTA C, SALVAGGIO A et al: Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 88(2):574–579.
   PubMed Web of Science ®Google Scholar
• HADIDA F, VIEILLARD V, AUTRAN B, CLARK-LEWIS I, BAGGIOLINI M, DEBRE P: HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J. Exp. Med. (1998) 188(3):609–614.
   PubMed Web of Science ®Google Scholar
• FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G-protein-coupled receptor. Science (1996) 272:872–877.
   PubMed Web of Science ®Google Scholar
• DRAGIC T, LITWIN V, ALLA WAY GPet al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR5. Nature (1996) 381:667–673.
   Google Scholar
• DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 318:661–666.
   Google Scholar
• BLEUL CC, FARZAN M, CHOE H et al: The lymphocytes chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382:829–833.
   PubMed Web of Science ®Google Scholar
• OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833–835.
   PubMed Web of Science ®Google Scholar
• CONNORS RI, SHERIDAN KE, CERADINI D, CHOE S, LANDAU NR Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. I Exp. Med. (1997) 185:621–628.
   PubMed Web of Science ®Google Scholar
• XIAO L, RUDOLPH DL, OWEN SM, SPIRA TJ, LAL RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. A/DS (1998) 12(13):F137–F143.
   Google Scholar
• VALENTIN A, ALBERT J, FENYO EM, ASJO B: Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus Type 1 and 2 isolates. J. ViroL (1994) 68(10):6684–6689.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, WILKINSON D, REEVES JD et al.: Primary, syncytium-inducing human immunodeficiency virus Type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. ViroL (1996) 70(12):8355–8360.
   PubMed Web of Science ®Google Scholar
• MCKNIGHT A, WEISS R: Blocking the docking of HIV-1. Proc. Natl. Acad. Sci. USA (2003) 100(19):10581–10582.
   PubMed Web of Science ®Google Scholar
• ••An excellent commentary on the strategyof blocking the very early phases of HIV-1 interaction with cells.
   Google Scholar
• KILBY JM, HOPKINS S,VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. (1998) 4:1302–1307.
   Google Scholar
• ••Enfuvirtide in the first proof of concept trial as the lead compound in a novel therapeutic class.
   Google Scholar
• LALEZARI J, HENRY K, O'HEARN M et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl. Med. (2003) 348:2175–2185.
   Google Scholar
• JACOBSON JM, LOWY I, FLETCHER CV et al: Single-dose safety, pharmacology, and antiviral activity of human immunodeficiency virus (HIV) Type 1 entry inhibitor PRO-542 in HIV-infected adults. J. Inf Dis. (2000) 182:326–329.
   PubMed Web of Science ®Google Scholar
• LIN P-F, BLAIR W, WANG T et aL: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. NatL Acad. Sci. USA (2003) 100:11013–11018.
   PubMed Web of Science ®Google Scholar
• FISCHER R, BERTONIS J, MEIER W et al.: HIV infection is blocked M vitro by recombinant soluble CD4. Nature (1988) 331:76–78.
   PubMed Web of Science ®Google Scholar
• DAAR ES, LI XL, MOUDGIL T, HO DD:High concentration of recombinant soluble CD4 are required to neutralize human immunodeficiency virus Type 1 isolates. Proc. NatL Acad. Sci. USA (1990) 87:6574–6578.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY RT, MERIGAN TC, GAUG P et al.: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann. Intern. Med. (1990) 112:247–253.
   PubMed Web of Science ®Google Scholar
• ALLA WAY G, DAVIS-BRUNO KL, BEAUDRY GA et al.: Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV Type 1 isolates. AIDS Res. Hum. Retrovimses (1995) 11(5):533–539.
   PubMed Web of Science ®Google Scholar
• SHEARER WT, ISRAEL RJ, STARR S et al.: Recombinant CD4-IgG2 in human immunedeficiency virus Type 1-infected children: Phase 1/2 study. I Infect. Dis. (2000) 182:1774–1779.
   PubMed Web of Science ®Google Scholar
• JACOBSON JM, ISRAEL RJ, LOWY I et al.: Treatment of advanced human immunodeficiency virus Type 1 disease with the viral entry inhibitor PRO-542. Antimicrob. Agents Chemother: (2004) 48(2):423–429.
   PubMed Web of Science ®Google Scholar
• WANG T, ZHANG Z, WALLACE OB et al.: Discovery of 4-benzoy1-1-[(4-methoxy-1H- pyrrolo [2, 3-b]pyridin-3-yl) oxoacetyll -2- (h) -methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. Med. Chem. (2003) 46(20):4236–4239.
   Web of Science ®Google Scholar
• GUO Q, HO HT, DICKER I et al.: Biochemical and genetic characterizations of a novel human immunodeficiency virus Type 1 inhibitor that blocks gp120-CD4 interactions. .1 Viral. (2003) 77(19):10528–10536.
   Google Scholar
• HANNA G, LALEZARI J, HELLINGERJ et al.: Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. I I th Conference on Retro viruses and Opportunistic Infections. San Francisco, USA (2004) 141.
   Google Scholar
• SCOZZAFAVA A, MASTROLORENZ OA, SUPURAN CT: Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. I Enzyme Inhib. Med. Chem. (2002) 17(2):69–76.
   PubMed Web of Science ®Google Scholar
• ••A very comprehensive review on newchemokine receptor antagonists.
   Google Scholar
• NARDESE V, LONGHI R, POLO S et al.: Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat. Struct. Biol. (2001) 8(7):611–615.
   PubMedGoogle Scholar
• PROUDFOOT AEI, POWER CA, HOOGEWERF AJ et al.: Extension of recombinant human RANTES by retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. (1996) 271:2599–2603.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, CLAPHAM PR, PICARD L et al: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276:276–279.
   PubMed Web of Science ®Google Scholar
• MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215–1224.
   PubMed Web of Science ®Google Scholar
• MOSIER DE, PICCHIO GR, GULIZIA RJet al.: Highly potent RANTES analogues either prevent CCR5 - using human immunodeficiency virus Type 1 infection in vivo or rapidly select for CXCR4-using variants.' Virol. (1999) 73(5):3544–3550.
   Google Scholar
• SABBE R, PICCHIO GR, PASTORE C et al.: Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. Viral. (2001) 75 (2):661–671.
   PubMed Web of Science ®Google Scholar
• BABA M, NISHIMURA 0, KANZAKI N et al.: A small molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Nati Acad. ScL USA (1999) 96:5698–5703.
   Google Scholar
• SHIRAISHI M, ARAMAKI Y, SETO M et al.: Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med. Chem. (2000) 43(10):2049–2063.
   PubMed Web of Science ®Google Scholar
• TAKASHIMA K, MIYAKE H, FURUTA RA et al.: Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus Type 1 envelope-mediated membrane fusion and viral replication. Antimicrob. Agents Chemother. (2001) 45(12):3538–3543.
   PubMed Web of Science ®Google Scholar
• IMAMURA S, ISHIHARA Y, HATTORI T et al.: CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives. Chem. Pharm. Bull. (Tokyo) (2004) 52(1):63–73.
   Google Scholar
• STRIZKI JM, XU S, WAGNER NE et al: SCH-C (SCH-351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection M vitro and in vivo. Proc. Natl. Acad. Sci. USA (2001) 98(22):12718–12723.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, KUHMANN SE, STRIZKI JM et al: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl Acad. Sci. USA (2002) 99(1):395–400.
   PubMed Web of Science ®Google Scholar
• KUHMANN SE, PUGACH P, KUNSTMAN KJ et al.: Genetic and phenotypic analyses of human immunodeficiency virus Type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. (2004) 78(6):2790–2807.
   PubMed Web of Science ®Google Scholar
• TSAMIS F, GAVRILOV S, KAJUMO F et al.: Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus Type 1 entry../. Virol. (2003) 77(9) :5201–5208.
   Google Scholar
• OLSON WC, RABUT GEE, NAGASHIMA KA et al: Differential inhibition of human immunodeficiency virus Type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to C CR5. J. Vim/. (1999) 73(5):4145–4155.
   Google Scholar
• TRKOLA A, KETAS TJ, NAGASHIMA KA et al: Potent, broad-spectrum inhibition of human immunodeficiency virus Type 1 by the CCR5 monoclonal antibody PRO-140. .1 Virol. (2001) 75(2):579–588.
   Google Scholar
• YANG 00, SWANBERG SL, LU Z et al.: Enhanced inhibition of human immunodeficiency virus Type 1 by Met-stromal-derived-factor-1I3 correlates with down-regulation of CXCR4. j Vim/. (1999) 73:4582–4589.
   Google Scholar
• RUSCONI S, MERRILL DP, LA SETA CATAMANCIO S et al.: ha vitro inhibition of HIV-1 by Met-SDF-1I3 alone or in combination with antiretroviral drugs. Antivir. Ther. (2000) 5(3):199–204.
   Google Scholar
• O'BRIEN WA, SUMNER-SMITH M, MAO SH, SADEGHI S, ZHAO JQ, CHEN IS: Anti-human immunodeficiency virus Type 1 activity of an oligocationic compound mediated via gp120 V3 interactions .Viral. (1996) 70(5):2825–2831.
   Google Scholar
• DORANZ B, GROVIT-FERBAS K, SHARRON M et al.: A small molecule inhibitor directed against chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. Exp. Med. (1997) 186:1395–1400.
   PubMed Web of Science ®Google Scholar
• MASUDA M, NAKASHIMA H, UEDA T et al.: A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys71-polyphemusin II). Biochem. Biophys. Res. Commun. (1992) 189(2):845–850.
   PubMed Web of Science ®Google Scholar
• MURAKAMI T, ZHANG TY, KOYANAGI Y et al.: Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus Type 1 infection. Virol. (1999) 73(9):7489–7496.
   Web of Science ®Google Scholar
• SCHOLS D, ESTE' JA, HENSON G, DE CLERCQ E: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. (1997) 35(3):147–156.
   PubMed Web of Science ®Google Scholar
• DONZELLA GA, SCHOLS D, LIN SW et al: AMD-3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med (1998) 4:72–77.
   PubMed Web of Science ®Google Scholar
• CHAN DC, KIM PS: HIV entry and its inhibition. Cell (1998) 93:681–684.
   PubMed Web of Science ®Google Scholar
• ••This pivotal paper describes the principlesof inhibiting HIV-1 entry into target cells.
   Google Scholar
• ECKERT DM, MALASHKEVICH VN, HONG LH, CARR PA, KIM PS: Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell (1999) 99(1):103–115.
   PubMed Web of Science ®Google Scholar
• FERRER M, KAPOOR TM, STRASSMAIER T et al.: Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Strad-. Biol. (1999) 6(10):953–960.
   PubMedGoogle Scholar
• ROOT MJ, KAY MS, KIM S: Protein design of an HIV-1 entry inhibitor. Science (2001) 291(5505):884–888.
   PubMed Web of Science ®Google Scholar
• LAMBERT DM, ZHOU J, MEDINAS R et al.: HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T1249. Antiviral Ther. (1999) 4\(Supp1.1):8.
   Google Scholar
• LAZZARIN A, CLOTET B, COOPER D et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl. I Med. (2003) 348(22):2186–2195.
   PubMed Web of Science ®Google Scholar
• GULICK R, ERON J, BARTLETT JA et al.: Complete analysis of T1249-101: Safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of HIV membrane fusion. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (2002) H–1075.
   Google Scholar
• LALEZARI J, BELLOS N, RICHMOND G et al.: Final analysis of T1249-102: T-1249 retains potent short term antiviral activity in patients who have failed a regimen containing enfuvirtide. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2003) H–444.
   Google Scholar
• MAEDA K, NAKATA, H, MIYAKAWA T et al.: AK602: a novel HIV-specific spirodiketopiperazine CCR5 inhibitor potent against a wide spectrum of R5-HIV. 10th Conference on ReMoviruses and Opportunistic Infections. Boston, USA (2003) 10.
   Google Scholar
• IIZAWA Y, KANZAKI N, TAKASHIMA Ket al.: Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist. 10th Conference on Retro viruses and Opportunistic Infections. Boston, USA (2003) U.
   Google Scholar
• DORR P, MACARTNEY M, RICKETT G et al.: UK-427857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. 10th Conference on Retrovimses and Opportunistic Infections. Boston, USA (2003) 12.
   Google Scholar
• POZNIAK A, FATKENHEUER G, JOHNSON M et al.: Effect of short-term monotherapy with UK-427857 on viral load in HIV-infected patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2003) H–443.
   Google Scholar
• MOORE JP, SATTENTAU QJ, KLASSE PJ, BURKLY LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus Type 1 (HIV-1) and HIV-1 infection of CD4+ cells.' Vim/. (1992) 66(8):4784–4793.
   Google Scholar
• KURITZKES DR, JACOBSON J, POWDERLY WG et at: Antiretroviml activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV Type 1. J. Infect. Dis. (2004) 189(2):286–291.
   PubMedGoogle Scholar
• STIEGLER G, KATINGER H: Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. Antimicrob. Chemother. (2003) 51(4):757–759.
   Google Scholar
• ARMBRUSTER C, STIEGLER GM, VCELAR BA et al: A Phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS (2002) 16(2):227–233.
   PubMed Web of Science ®Google Scholar
• STIEGLER G, ARMBRUSTER C, VCELAR B et al.: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a Phase I evaluation. AIDS (2002) 16(15):2019–2025.
   PubMed Web of Science ®Google Scholar
• CHOU T-C, TALALAY P: Quantitative analysis of dose effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv. Enzyme Regal (1984) 22:27–55.
   PubMedGoogle Scholar
• TREMBLAY CL, KOLLMAN C, GIGUEL F, CHOU T-C, HIRSCH MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. JAIDS (2000) 25(2):99–102.
   Google Scholar
• TREMBLAY CL, GIGUEL F, KOLLMAN C et al.: Anti-human immunodeficiency interactions of SCH-C (SCH-351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. (2002) 46(5):1336–1339.
   PubMed Web of Science ®Google Scholar
• RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al: Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus Type 1 infection: in vitro studies of mixed virus infections. J Virol. (2000) 74(19):9328–9332.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA KA, THOMPSON DA, ROSENFIELD SI, MADDON, PJ, DRAGIC T, OLSON WC: Human immunodeficiency virus Type 1 entry inhibitors PRO-542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. Infect. Dis. (2001) 183:1121–1125.
   Web of Science ®Google Scholar